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1. Introduction   
Despite the advent of biologics, rheumatoid arthritis continues to be closely linked with 
pain, functional impairment, and depression, and a significant number of those with 
moderate to severe rheumatoid arthritis are too disabled to work several years after onset 
(Sokka et al., 1999). Furthermore, biologics have increased medical costs to nearly 
$20,000/patient/year and side effects have hindered use by those with more advanced 
symptoms (Lundkvist et al., 2008). “Old” disease modifying anti-rheumatic drugs 
(DMARDs) are also linked to negative consequences as a result of non-specific organ 
toxicity. The exact cause of rheumatoid arthritis has not yet been identified and, 
consequently, treatment methods have not been optimally effective. Drug delivery systems 
may serve to reduce the necessary dosage and increase therapeutic efficacy of old and new 
rheumatoid arthritis treatments.  
Numerous materials have been proposed as drug delivery systems for cancer, and, in recent 
years, the use of such materials has been increasingly extended to the treatment of 
rheumatoid arthritis. Liposomes, nanoparticles, micelles, and macromolecule-drug 
conjugates can be used to increase a drug’s circulatory stability and thereby raise the 
probability for passive accumulation within the pannus, where permeability is enhanced. 
Both the specificity and therapeutic efficacy of these drug delivery systems can be further 
improved by combination with an active targeting moiety, such as an antibody, peptide, or 
polysaccharide that is specific for receptors concentrated on the surface of cells located 
within tissue affected by rheumatoid arthritis. The combination of passive and active 
targeting strategies can be used to optimize delivery of therapeutic agents to reduce toxicity 
and unwanted side effects and improve patient outcome. This chapter is intended to 
provide an overview of emerging techniques aimed at improving the efficacy of DMARDs, 
whilst simultaneously reducing the adverse consequences associated with non-specific 
targeting. Due to the nature of the disease, this review will focus only on drug delivery 
systems intended for systemic, rather than local/intra-articular, administration.  
2. History and challenges of rheumatoid arthritis treatment 
Historically, rheumatoid arthritis has been treated with a combination of anti-inflammatory 
drugs and immunosuppressants. Although treatment has evolved from non-steroidal anti-
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inflammatory drugs (NSAIDs) to  disease modifying anti-rheumatic drugs (DMARDs), 
including modern biologics, all of the drugs in use have severe, potentially life threatening, 
consequences due to non-specific targeting, often in combination with impaired immune 
function.  
Rheumatoid arthritis treatment originated wtih NSAIDs, such as aspirin and other 
salicylates, which act as anti-inflammatory agents by interfering with the activity of 
cyclooxygenase (COX) enzymes and, consequently, the production of prostaglandins (PGs), 
which are key mediators of the inflammatory response. Despite a lack of efficacy relative to 
conventional DMARDs or biologics, NSAID use in combination therapy has continued 
(Mottram, 2003). The long term side effects of NSAIDs include gastrointestinal and 
cardiovascular complications, as well as impaired renal function (Dijkmans et al., 1995).  
Similar to NSAIDs, glucocorticoids (GCs), including cortisone, dexamethasone, 
prednisolone, and prednisone, primarily act through inhibition of PG production and are 
still used in current rheumatoid arthritis treatment strategies. Additionally, GCs reduce the 
expression of several proinflammatory proteins, including interleukin-1, -2, and -6, 
granulocyte macrophage-colony stimulating factor (GM-CSF), and tumor necrosis factor- 
(TNF-) (Moreland & O'Dell, 2002). Although high doses can be immunosuppressive, as 
well as anti-inflammatory, doses are typically kept low in rheumatoid arthritis treatment to 
minimize the adverse consequences that include gastrointestinal complications, an increased 
risk of osteoporosis, visual problems, and negative skin effects (Strand & Simon, 2003).  
In the 1920s, gold salts were used to treat rheumatoid arthritis based upon the belief that the 
disease was triggered by an infection (Mottram, 2003). Although the link to a bacterial origin 
has been dispelled, gold has been classified as the earliest form of  DMARD. The  side effects 
of gold include reduced liver and renal function, as well as pulmonary complications. 
Consequently, the use of gold as a treatment is now limited to only severe rheumatoid 
arthritis patients who do not respond to other  DMARDs.,  
Several cytotoxic, anti-cancer agents have been adapted as DMARDs. For example, 
methotrexate has been in use as an oncology drug since 1950 and as a DMARD since 1970. 
Although the mechanism of action in rheumatoid arthritis remains largely unclear, 
methotrexate is speculated to either reduce proliferation  of  infiltrating inflammatory cells 
or suppress the release of pro-inflammatory cytokines (Mottram, 2003). Despite periodic 
liver function tests and biopsies for patients undergoing methotrexate treatment, cirrhosis 
and fibrosis are known side effects, and fatalities have been reported (Goodman & Polisson, 
1994; Wolverton & Remlinger, 2007).  
Other common DMARDs include immunosuppressants originally developed to prevent 
organ transplant rejection, such as cyclosporine, tacrolimus, and sirolium. The 
immunosuppressive properties of the latter drugs appear to be primarily due to inhibition 
of T-cell activation (Mottram, 2003).  All of these therapeutics are nephrotoxic; consequently, 
creatinine levels must be monitored during treatment to assess renal dysfunction and 
kidney damage (Schiffelers et al., 2006; Zachariae, 1999). 
A better understanding of disease progression, particularly as pertains the imbalance in pro- 
and anti-inflammatory cytokines, has led to the recent development of a number of biologic 
therapies as DMARDs, for example anti-TNF−ǂ monoclonal antibodies such as infliximab and 
adalimumab. Although the latter agents are intended to be more specific, systemic inhibition 
of key inflammatory molecules can also have negative consequences. In particular, patients 
receiving treatment with biologics have an increased incidence of serious infections. 
Furthermore, the efficacy in individual patients is often unpredictable (Strand et al., 2007).  
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The pharmacokinetic profiles of most DMARDs are unfavorable (Tarner & Muller-Ladner, 
2008). For example, the bioavailability, peak serum concentration, and half life of orally 
administered methotrexate varies considerably between patients. The large variability in 
pharmacokinetic parameters likely contributes to the toxicity observed in some patients 
(Weinblatt & Kremer, 1988). Given the high incidence of adverse side effects, in addition to 
variability in drug effectiveness, the application of drug delivery srategies would be a 
significant advancement in rheumatoid arthritis treatment. 
3. Principles of drug delivery 
3.1 Passive targeting 
In cancer treatment, drug carrier systems with a large hydrodynamic radius to prevent renal 
filtration and increase circulation time can passively target diseased tissue as a result of 
leaky vasculature and inadequate lymphatic drainage, an effect known as ”enhanced 
permeation and retention” (EPR) (Gillies & Frechet, 2005; Lee et al., 2006; Padilla De Jesus et 
al., 2002). Although inflammatory tissue, as found with rheumatoid arthritis,  does not 
display abnormal lymphatic drainage (Xu et al., 2003), long-circulating delivery systems 
have been shown to selectively accumulate within the inflamed synovial tissue, i.e. the 
pannus (Fiehn et al., 2004; Metselaar et al., 2002; Schiffelers et al., 2006; Vanniasinghe et al., 
2008; Wunder et al., 2003). The pannus possesses an increased vascular permeability similar 
to that of solid tumors and, consequently, the vasculature can be exploited for passive 
targeting in an analogous manner (Walsh, 1999). Fig. 1 illustrates the principles behind 
passive and active targeting of inflamed joint tissue. 
 
 
Fig. 1. Drug delivery strategies in the treatment of rheumatoid arthritis. Passive targeting of 
the pannus can be achieved by creating carriers that can only pass through leaky 
vasculature, while active targeting can be facilitated by a ligand that is specific for receptors 
of rheumatoid arthritis synovial fibroblasts (RASFs), rheumatoid arthritis synovial 
macrophages (RASMs), or activated vascular endothelial cells (VECs).  
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3.2 Active targeting 
In addition to the potential for passive targeting, the two primary cell types found within 
the pannus tissue, rheumatoid arthritis synovial fibroblasts (RASFs) and rheumatoid 
arthritis synovial macrophages (RASMs) selectively express surface receptors, such as CD44 
(Haynes et al., 1991; Johnson et al., 1993), folate receptor (Nagayoshi et al., 2005; van der 
Heijden et al., 2009), and integrin V3 (Wilder, 2002) that are candidates for active targeting. 
Angiogenic vascular endothelial cells (VECs) are also present as a result of 
neovascularization, and the E-selectin adhesion molecule has been identified as another 
viable target for drug delivery (Jamar et al., 2002). 
3.3 Carrier systems 
In general, drug delivery systems can be divided into two categories: polymer-drug 
conjugates and nanoparticulate carrier systems. “Nanoparticles” in this sense include 
liposomes and micelles, as well as traditional metallic and polymeric nanoparticles. As drug 
delivery systems have become increasing advanced, the distinction between these two 
categories has become less clear.   
3.3.1 Polymer-drug conjugates 
In 1975, Ringsdorf proposed a model for polymer-based drug delivery wherein discrete 
sections of a polymer backbone are used for attachment of therapeutics, solubilizers, and 
targeting moieties (Fig. 2) (Ringsdorf, 1975). Since this seminal manuscript, numerous 
macromolecular therapeutics have been synthesized and evaluated. Although initial 
research focused on the use of N-(2-hydroxypropyl) methacrylamide (HPMA) based upon 
similarity to Ringsdorf’s Model, polymers with a variety of architectures and structural 
elements are currently being explored, including linear mono- and di-functional polymers, 
star polymers, and dendrimers (Fig. 3) (Kopecek et al., 2000; Peterson et al., 2003). 
Dendrimers can alternatively be classified as nanoparticulate carriers when drug molecules 
are entrapped within the interior rather than covalently linked to the surface functional 
groups (Gillies & Frechet, 2005; M. Liu & Frechet, 1999). Mono- and di-hydroxyl terminated 
poly(ethylene glycol) (PEG) have proven to be the most versatile polymers for increasing the 
stability, solubility, and pharmacokinetic properties of associated therapeutics, with several 
PEG-drug conjugates on the market for a number of indications (Joralemon et al., 2010). 
Only recently has this research translated to the development of macromolecular 
therapeutics for the treatment of rheumatoid arthritis, as discussed further in Section 4. 
Despite demonstrated success, polymer-drug conjugates suffer from the necessity to 
chemically modify the drug molecule and the potential to reduce therapeutic activity and 
efficacy by such modification (Haag & Kratz, 2006; Kim et al., 2009).  
 
 
Fig. 2. (A) Ringsdorf’s model of polymer-drug conjugates for drug delivery. (B)  HPMA was 
investigated for use due to similarity to Ringsdorf’s model.  
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Fig. 3. Various polymer architectures investigated for use in drug delivery via polymer-drug 
conjugates. (A) Linear polymers, with PEG as an example, (B) star, polymers and (C) 
dendrimers.  
3.3.2 Nanoparticulate carrier systems 
Nanoparticulate carrier systems permit entrapment/encapsulation of therapeutics without 
modification, as is requisite for polymer-drug conjugates. The colloidal particles can range 
in size from 10 nm to 1 m; however, sizes are more typically between 20 and 300 nm, 
thereby minimizing uptake by macrophages of the reticuloendothelial system, while 
permitting passive targeting of tissue with leaky vasculature. Liposomes, micelles, metallic 
nanoparticles, and polymeric nanoparticles constitute the most commonly used 
nanoparticulate carrier systems for drug delivery (Fig. 4) (Jain, 2008).  
 
 
Fig. 4. Various nanoparticulate carrier systems. (A) Micelles, (B) liposomes, and (C) 
polymeric nanoparticles.  
Liposomes are vesicles formed from phospholipid bilayers with aqueous centers. 
Consequently, liposomes are used to encapsulate both hydrophobic and hydrophilic drugs 
within the bilayer and the aqueous core, respectively.  Liposomal properties are largely 
controlled through the choice of phospholipids, as well as the addition of sterols, 
particularly cholesterol, and glycolipids (Jain, 2008). Although conventional liposomes 
suffer from rapid uptake by the reticuloendothelial system, incorporation of PEG into the 
bilayer yields so called “stealth” liposomes with enhanced circulation times. Starting with 
the anticancer compound Doxil (Gabizon, 2001), several PEG-modified liposomes with 
encapsulated therapeutics have reached commercialization (Joralemon, et al., 2010). As a 
consequence, liposomal use has been widely studied as a potential carrier system for drug 
delivery for rheumatoid arthritis (Foong & Green, 1993; Konigsberg et al., 1999; Monkkonen 
et al., 1993; Monkkonen & Heath, 1993; Monkkonen et al., 1994; Shaw et al., 1979) .  
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Above a certain concentration, referred to as the critical micelle concentration (CMC), 
molecules that possess both hydrophobic and hydrophilic segments, such as amphipathic 
block-co-polymers, will self assemble to form colloidal particles with hydrophobic interiors 
and hydrophilic exteriors. Micelles are typically smaller than liposomes (20-50 nm) and the 
hydrophobic cores are used to entrap drugs that possess low aqueous solubility (Haag & 
Kratz, 2006). The CMC provides an indicator of stability, where systems with low CMCs are 
not easily disrupted or disintegrated (Oerlemans et al., 2010). Only a handful of 
investigators have used micelle-based drug delivery systems to improve the efficacy of 
DMARDs that have historically suffered from unpredictable pharmacokinetics resultant 
from poor solubility (Bader et al., 2011; Koo et al., 2011; Zhang et al., 2007).  
Both metallic and polymeric nanoparticles are used to encapsulate drugs within the solid 
core. Although nanoparticles are defined as any system with a submicron ( 1 m) size (van 
Vlerken & Amiji, 2006), most typically have sizes below 200 nm (Jain, 2008). Metallic 
nanoparticles include iron-oxide nanoparticles, silica-gold nanoshells, gold nanoparticles, 
and Quantum dots (cadmium, selenium, and zinc) (Riehemann et al., 2009; van Vlerken & 
Amiji, 2006). Although originally developed for cancer treatment, these technologies are 
currently being translated to rheumatoid arthritis treatment applications (Corthey et al., 
2010). The use of metals can yield multifunctional nanoparticles whereby both therapeutic 
delivery and imaging are facilitated (Riehemann et al., 2009). Polymer-based nanoparticles, 
are advantageous in that modification permits the ready addition of the following elements: 
targeting ligands, environment-sensitive drug release, and biologically functional polymers.   
The carrier systems discussed above can be further modified to optimize disease treatment. 
For example, co-administration of multiple therapeutics from one convenient platform is 
feasible.  Additional modification with ligands specific for receptors found on diseased cells 
can facilitate active targeting. Furthermore, surface coating with PEG can be used to tailor 
circulation time (Riehemann et al., 2009; van Vlerken & Amiji, 2006). As detailed in Section 
4, these technologies have only recently been applied in the realm of drug delivery for 
rheumatoid arthritis treatment.   
3.3.3 Therapeutic release from carrier systems  
Most drugs are inactive when bound to/encapsulated within the carrier system; therefore, a 
method that permits drug release at the diseased site is often requisite. Cellular uptake of 
therapeutic-loaded carrier systems typically proceeds by fluid-phase endocytosis, 
adsorptive endocytosis, or receptor-mediated endocytosis (Fig. 5). During each of these 
endocytotic processes, the pH drops from that within the extracellular space (pH ≈ 7.4 for 
healthy tissue and pH < 7.4 for diseased tissue) to pHs of ~6.0 and ~4.0 in the endosomes 
and lysosomes, respectively (Haag & Kratz, 2006; Petrak, 2005). Thus, the conjugate and 
particulate carriers can be formulated such that release is only permitted at a specified pH. 
Alternatively, drugs may be released after enzymes cause non-specific hydrolysis (Haag & 
Kratz, 2006; Kim et al., 2009). An ideal carrier system will only respond to environmental 
features unique to the diseased tissue, such as elevated levels of a specific enzyme. Stimuli-
responsive drug delivery systems that are currently in development for the treatment of 
rheumatoid arthritis will be discussed in Section 5.  
4. Current drug delivery systems and strategies for rheumatoid arthritis 
A number of carrier systems have been designed to to improve rheumatoid arthritis 
treatment based upon the principles described in Section 3. These carrier systems provide an 
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opportunity to increase the efficacy of existing rheumatoid arthritis therapeutics while 
reducing adverse effects.   A summary of current drug delivery strategies that encompasses 
Sections 4 and 5 is given in Table 1.     
4.1 Polymer-drug conjugates for rheumatoid arthritis treatment 
Several polymer-drug conjugates have been developed to improve the therapeutic efficacy 
of both conventional DMARDs and biologics. A number of these compounds were only 
recently applied to rheumatoid arthritis after originally being developed for cancer. For 
example, methotrexate conjugated to human serum albumin (MTX-HSA) was shown to 
passively accumulate within the inflamed paws of arthritic mice. Further study revealed a 
reduction in cellular invasion, a downregulation of proinflammatory cytokine levels, and a 
decrease in cartilage damage for arthritic mice treated with MTX-HSA relative to untreated, 
arthritic mice. The conjugates were also useful in preventing the onset of arthritis in mice 
when administered prior to induction (Fiehn et al., 2004; Wunder et al., 2003). Due to the 
limitations of exogenous albumin, a methotrexate pro-drug has recently been developed 
that will react with endogenous albumin upon administration (Fiehn et al., 2008). 
 
 
Fig. 5. Cellular uptake of carrier systems occurs by an endocytotic process.   Systems can be 
designed to release their therapeutic payload within the extracellular space, the endosome, 
or the lysosome.  
As mentioned in Section 3, PEG has been used extensively in all areas of drug delivery. 
PEG-dexamethasone conjugates were recently synthesized that reduced joint inflammation 
when administered intravenously to arthritis rats (Liu et al., 2010). PEGylation has been 
applied to biologics, in addition to conventional, small molecule therapeutics. To the 
authors‘ knowledge, the only polymer-drug conjugate to reach clinical trials for rheumatoid 
arthritis treatment thus far is certolizumab pegol (CDP870), a PEG conjugated TNF- 
antibody fragment originally developed for treatment of Chron’s disease (Barnes & Moots, 
2007). Administration to a number of patients who did not respond well to conventional 
DMARDs, particularly methotrexate, led to a reduction in disease activity and joint damage. 
Unfortunately, an increase in adverse side effects was also observed (Ruiz Garcia et al.,  
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Type of 
Carrier  
 
 
Material(s) 
 
 
Targeting 
Group 
 
Therapeutic 
 
 
Reference(s) 
 
 
 
Polymer-
Drug 
Conjugate 
Albumin ― Methotrexate (Wunder et al., 2003) 
PEG ― Cathepsin-K 
Inhibitor 
(Wang et al., 2004) 
 HPMA ― Cathepsin-K 
Inhibitor 
(Wang et al., 2004) 
 PEG ― TNF- 
Antibody 
Fragment
(Barnes & Moots, 2007) 
 PEG  ― Dexamethasone (Liu, et al., 2010) 
 HPMA ― Dexamethasone (Quan et al., 2010) 
 PAMAM Dendrimer Folate Methotrexate (Thomas et al., 2011) 
Liposome Phospholipids 
Cholesterol 
― Clondronate (Camilleri et al., 1995; 
Love et al., 1992)  
 Phospholipids (with 
and without 
covalently linked 
methotrexate) 
Cholesterol
― Methotrexate  (A. S. Williams, Camilleri, 
& Williams, 1994) 
 Phospholipids 
Cholesterol 
PEG  
― Superoxide 
Dismutase  
Corvo et al., 1999) 
 Phospholipids 
Cholesterol  
PEG 
― Prendisolone (Metselaar et al., 2002; 
Metselaar et al., 2003) 
 Phospholipids 
Cholesterol 
Sialyl 
Lewis X  
 (Hirai et al., 2007) 
 Phosphogliv ― Methotrexate (Zykova et al., 2007) 
 PEG-Phospholipids Vasoactive 
Intenstinal 
Peptide 
Camptothecin (Koo et al., 2011) 
 Cationic 
Phospholipids 
― anti-TNF-IL-
1 IL-6/ IL-18 
siRNA
(Khoury et al., 2008; 
Khoury et al., 2006) 
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Micelle PEG-
Poly(caprolactone)  
― Cyclosporine A (Aliabadi et al., 2005) 
 Dextran-
Polyoxyethylene Cetyl 
Ether (POE-C16) 
― Cyclosporine A (Francis et al., 2005) 
 Hydroxypropyl-
cellulose-(POE-C16) 
― Cyclosporine A (Francis et al., 2005) 
 Polysialic Acid-
Decylamine 
― Cyclosporine A (Bader et al., 2011) 
Nanoparticle PLGA ― Betamethasone (Higaki et al., 2005) 
 PLGA-PEG ― Betamethasone (Ishihara et al., 2009) 
 PAMAM Dendrimer Folate Indomethacin (Chandrasekar et al., 
2007b) 
 Polyester Ligand for 
E-Selectin 
― (Banquy et al., 2008). 
 Cyclodextrin ― Methyl-
prendisolone 
(Hwang et al., 2008)  
 PLGA-PEG cLABL 
Peptide 
― (Zhang et al., 2008) 
 PEG-TRAIL
Hyaluronic Acid 
Hyaluronic 
Acid 
TRAIL (Kim et al., 2010), 
 Gold Core-Gold(I)-
Thiomalate 
― Gold (Corthey, et al., 2010) 
 Chitosan Folate IL-1R Agonist (Fernandes et al., 2008) 
 Lipid
PEG 
Folate NF-B Decoy (Hattori et al., 2006), 
Table 1. Current drug delivery strategies for rheumatoid arthritis  
2011), suggesting that PEGylation may not be the ideal method to improve the efficacy of 
rheumatoid arthritis therapeutics.  
Other polymer-drug conjugates have shown some promise in vitro, such as PEG and HPMA 
conjugated cathepsin-K inhibitor (Wang et al., 2004).  Furthermore, as will be desribed in 
more detail in Section 5, systems such as PEG and HPMA dexamethasone conjugates are 
now being developed that, not only target the pannus tissue, but also selectively release the 
therapeutic in the targeted region (Liu, et al., 2010; Quan et al., 2010).  
4.2 Liposomal carrier systems for rheumatoid arthritis treatment 
Several liposome systems have been tried for improved efficacy of rheumatoid arthritis 
treatments. This work was pioneered by Williams, et. al., who demonstrated that 
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technecium labelled liposomes accumulated within the synovial tissue of rheumatoid 
arthritis patients upon intravenous administration (Williams et al., 1986, 1987). A similar 
phenomenon was observed for phosphatidylcholine and cholesterol based liposomes given 
to arthritic rats (Love et al., 1989), and encapsulation of clondronate, an anti-inflammatory 
therapeutic that reduces bone resorption, resulted in a halt in disease progression and a 
reversal in inflammation (Camilleri et al., 1995; Love et al., 1992). The efficacy of the 
liposomal clondronate was attributed to depletion of the synovial macrophages (Love et al., 
1992; Richards et al., 1999).  Comparable results were obtained with liposomal methotrexate 
that was prepared by conjugation of the the Ǆ-carboxylic acid residue to the phospholipid. 
The resultant liposomes yielded a significant reduction of established joint inflammation, in 
combination with a decrease in toxicity, relative to comparable doses of free drug (Williams 
et al., 1994b. Furthermore, peritoneal macrophages isolated from the liposomal methotrexate 
treated arthritic rats were shown to express less TNF- and prostaglandin (PGE2) (Williams 
et al., 1994a). Conventional (i.e. not PEGylated) liposomes have also been used by other 
investigators to improve the efficacy of aurothiomalate (Konigsberg et al., 1999). 
Stealth liposomes have been used to improve the therapeutic efficacy of glucocorticoids, the 
use of which is often hindered by the necessity for frequent intravenous administration and 
by non-specific organ toxicity. Following on studies that showed an accumulation of PEG 
liposomes within the inflamed tissue of arthritic rats (Gabizon et al., 1994; Hong & Tseng, 
2003), Metselaar et al. (2002; 2003; 2004) investigated the efficacy of prednisolone loaded 
liposomes. Upon administration to arthritic rats and mice, the prednisolone liposomes 
reversed the inflammatory response, while free prednisolone had little effect on the course 
of the disease. The results were attributed purely to the passive targeting capacity of the 
stealth liposomes (Metselaar et al., 2004; Metselaar et al., 2002; Metselaar et al., 2003). 
Current research is focused upon extending the use of the stealth liposomes to other 
glucocorticoids, including dexamethasone and budesonide, and optimizing the therapeutic 
index (van den Hoven et al., 2011). PEG modified liposomes have also been used to improve 
the efficacy of superoxide dismutase (SOD), a free radical scavenger which suffers from a 
short half life. When encapsulated in small, stealth liposomes, the circulation of SOD was 
significantly extended, and the drug passively accumulated within the joint tissue (Corvo et 
al., 1999). 
4.3 Micelle carrier systems for rheumatoid arthritis treatment 
Despite  the low aqueous solubility of a number of DMARDs and glucocorticoids, micelles 
are a relatively unexplored drug delivery system for rheumatoid arthritis treatment. 
Camptothecin, originally developed as an anti-cancer drug, has recently been proposed as a 
new method of controlling pannus formation and reducing cartilage degradation. To 
circumvent problems with solubility and stability, micelles prepared from PEG-
phospholipids (Ashok et al., 2004) were used for drug encapsulation. The camptothecin 
micelles proved to be more effective than free camptothecin at abrogating inflammation 
when administered to arthritic mice. The efficacy of the micelles was further increased by 
modification with vasoactive intenstinal peptide (VIP) due to the over expression of VIP 
receptor by activated synovial macrophages (Koo et al., 2011). Similarly, micelles generated 
from a phospholipid preparation (Phosphogliv) and loaded with methotrexate were better 
able to reduce inflammation when administered to arthritic rats than the drug alone 
(Zykova et al., 2007).  
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Cyclosporine A is indicated for several different conditions; therefore, micelle-based 
methods for improving the solubility of of this DMARD have been more thoroughly 
researched. Cyclosporine has been successfully encapsulated by block copolymers of PEG 
and poly(caprolactone) (Aliabadi et al., 2005), PEG phospholipids (Lee et al., 1999), and 
hydrophobically modified polysaccharides, specifically dextran and hydroxypropylcellulose 
(Francis et al., 2005). Recently, polysialic acid, a relatively uninvestigated polysaccharide 
with propertiers similar to those of PEG in regards to minimizing uptake by the 
reticuloendotheial system, was used to encapsulate cyclopsorine for future use in 
rheumatoid arthritis treatment (Bader et al., 2011). The utility of the above cyclosporine 
micelles in vivo has not yet been demonstrated.  
4.4 Nanoparticle carrier systems for rheumatoid arthritis treatment 
Nanoparticle systems for delivery of rheumatoid arthritis therapeutics have primarily been 
based upon polymers. Numerous researchers have explored the use of poly(D,L-
lactic/glycolic acid) (PLGA) nanoparticles based upon their capacity to extend the circulation 
time and control the release of encapsulated drugs. In the realm of rheumatoid arthritis drug 
delivery, a glutocorticoid, betamethasone, was incorporated into PLGA nanoparticles with a 
size of 100-200 nm. Intravenous administration to arthritic rats and mice showed that the 
PLGA-betamethasone system was more effective at reducing the inflammatory response than 
the free glutocorticoid (Higaki et al., 2005). Targeting ability and, consequently, efficacy of the 
betamethasone was further improved by modifying the PLGA nanoparticles with PEG, 
forming so-called “stealth nanosteroids“ (Ishihara et al., 2009).   
Other polymeric nanoparticle systems involve covalently linking the drug molecule to one 
of the components so as to slow down therapeutic release, as occurs for polymer-drug 
conjugates, while still protecting the drug via encapsulation. For example, -
methylprednisolone was conjugated to cyclodextrin, and the resultant compound self-
assembled to yield nanoparticles with a size of approximately 27 nm. When administered 
intravenously at a frequency of one dose per week to arthritic mice, a significantly greater 
reduction in synovitis and pannus formation was acheieved than that obtained for free 
methylprednisolone administered daily at an equivalent cumulative dose (Hwang et al., 
2008). Another example is the ionic complexation of tumor necrosis factor (TNF)-related 
apoptosis inducing ligand (TRAIL) conjugated to PEG (PEG-TRAIL), which bears a positive 
charge, with negatively charged hyaluronic acid (HA) with sizes that range from 100 to 270 
nm, dependent upon the relative concentration of the two components. One formulation of 
the HA-PEG-TRAIL complex was capable of signficantly reducing the secretion of 
proinflammatory mediators relative to PEG-TRAIL alone when administered 
subcutaneously to arthritic mice (Kim et al., 2010), thereby emphasizing the importance of 
nanoparticulate carrier systems. The HA may also serve as an active targeting (Section 5). 
Despite the demonstrated efficacy of gold as a DMARD (Section 2), and the approval of gold 
nanoparticles for the treatment of rheumatoid arthritis by the FDA, little research has been 
conducted specifically directed towards the use of metallic nanoparticles for passive targeting 
in rheumatoid arthritis. The decline in the use of gold as a rheumatoid arthritis therapeutic 
was largely based on adverse side effects caused by non-specific toxicity.  However, the 
synthesis of gold core-gold(I)-thiomalate nanoparticles (Au@AU(I)-TM) was recently 
completed. Au@Au(I)-TM bears surface carboxylate groups which may be further modified 
for specific drug delivery applications (Corthey et al., 2010); therefore, these nanoparticles may 
pave the way to a renewed interest in the use of gold in the treatment of rheumatoid arthritis.   
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5. Future of drug delivery for rheumatoid arthritis 
The exploration of drug delivery systems for improved treatment of rheumatoid arthritis is 
still in the early stages. More advanced concepts that have been applied to other diseases, 
particularly cancer, are only beginning to be explored by rheumatoid arthritis researchers. 
5.1 Active targeting strategies 
Current drug delivery systems for rheumatoid arthritis have almost exclusively been 
developed based upon the principles of passive targeting. Specificity and, consequently, 
efficacy can be further improved by employing an active targeting moiety. As indicated 
previously, RASFs and RASMs possess receptors that can potentially be used to increase the 
ability of the drug carrier systems to discern pannus tissue from healthy tissue. Those 
receptors that have the highest potential for success are discussed in this section.  
Folate receptor ǃ (FRǃ) has been identified as a viable candidate for active targeting of RASMs. 
Several transport mechanisms exist whereby folate and folate antagonists, including 
methotrexate, can enter a cell. Numerous cell types throughout the body constitutively express 
the reduced folate carrier (RFC), a transmembrane protein. In contrast, membrane associated 
folate receptors (MFRs) are restricted in expression and facilitate uptake by endocytosis. The 
beta isoform of MFR (FRǃ) is expressed selectively by activated macrophages within the 
pannus tissue (Nagayoshi et al., 2005; van der Heijden et al., 2009). Thus, folate may serve as 
an effective means of actively targeting the pannus tissue. In support of this, folate-tagged 
cationic and anionic poly(amidoamine) (PAMAM) dendrimers loaded with indomethacin 
were more effective at treating arthritic rats than indomethacin-loaded dendrimers that were 
folate-free (Chandrasekar et al., 2007a; Chandrasekar et al., 2007b; Chauhan et al., 2004). 
Furthermore, a recent study demonstrated that PAMAM dendrimers covalently linked to both 
folate and methotrexate could be used to selectively deliver methotrexate to synovial 
macrophages (Thomas et al., 2011). Although the antifolate MTX does not have a high affinity 
for any MFRs, several other folate analogs have been identified that possess high affinity for 
FRǃ with low affinities for other MFRs and the RFC (van der Heijden et al., 2009). These 
analogs, therefore, have strong potential to be used as active targeting moieties in the future 
and may possess inherent anti-rheumatic properties.  
RASFs also possess an active targeting receptor in the cell surface adhesion molecule CD44, 
the hyaluronic acid receptor. Several studies have indicated that CD44 is upregulated in the 
pannus tissue relative to healthy, normal tissue (Haynes et al., 1991; Johnson et al., 1993). 
Furthermore, RASFs express numerous CD44 alternatively spliced variants, including long 
isoforms CD44v3 and CD44v6 that are associated with an enhanced invasive capacity (Croft 
et al., 1997). CD44 is critical to rheumatoid arthritis pathogenesis, facilitating inflammatory 
cell migration and signaling activation of lymphocytes (Naor & Nedvetzki, 2003). Despite 
evidence of upregulation and/or selective expression, the CD44 receptor has not yet been 
used as an active target for drug delivery in the treatment of rheumatoid arthritis. Some 
cancer cells also upregulate CD44, and the potential for success using this active targeting 
strategy has previously been illustrated by anti-cancer drug carrier systems modified with 
hyaluronic acid oligomers (Ossipov, 2010).  
As indicated by the feasibility of passive targeting, neovascularization is a critical 
component of rheumatoid arthritis pathogenesis (Szekanecz & Koch, 2008). Adhesion 
molecules, including intercellular cell-adhesion molecule-1 (ICAM-1) and E-selectin, are 
upregulated within the newly formed vasculature and; therefore, the endothelium serves as 
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another possibility for active targeting (Banquy et al., 2008; Zhang et al., 2008). Preliminary 
studies demonstrated that a large number of PLGA-PEG nanoparticles surface modified 
with a peptide specific for ICAM-1 were endocytosed by vascular endothelial cells as 
compared to unmodified particles (Zhang et al., 2008). A similar phenomenon was observed 
for polyester-based polymeric nanoparticles labeled with ligand specific for E-selectin 
(Banquy et al., 2008). Likewise, liposomes surface modified with the polysaccharide Sialyl 
Lewis X, which is known to bind selectively to E-selectin, were shown to accumulate within 
inflamed regions when administered intravenously to arthritic mice (Hirai et al., 2007). The 
vitronectin receptor, overexpressed by both angiogenic endothelial cells and RASMs 
(Tandon et al., 2005; Wilder, 2002), is an attractive target  based upon the extensive use of 
Arg-Glyc-Asp (RGD) tripeptide labeled carrier systems for drug delivery to invasive tumor 
tissue (Hsu et al., 2007). An antibody to V3, Vitaxin (ME-522), is currently being clinically 
developed for rheumatoid arthritis (Wilder, 2002); however, the RGD peptide sequence has 
not yeen been applied towards increasing the targeting ability and efficacy of existing 
DMARDs.  
5.2 Multifunctional carrier systems 
A recent push in the realm of drug delivery for cancer treatment has been the development 
of multifunctional carrier systems whereby a single platform can be used for the release of 
multiple therapeutics in a controlled fashion or for both therapeutic release and diagnostic 
imaging (Jabr-Milane et al., 2008; van Vlerken & Amiji, 2006). Some of the success achieved 
in this “theranostic” approach to cancer treatment has spilled over into the study of 
improved treatment methods for rheumatoid arthritis. For example, folate-conjugated 
radiopharmaceuticals designed to target malignant tissue showed significant accumulation 
in the joints of patients who also had rheumatoid arthritis (Paulos et al., 2004). Radiolabelled 
biologics have provided an additional example of the potential for theranostics to improve 
rheumatoid arthritis treatment. 99m-technetium labelled infliximab (99mTc-infliximab) was 
used to show a strong correlation between the amount of infliximab taken up by inflamed 
tissue and a reduction in symptoms and swelling (Malviya et al., 2010).  
5.3 Stimuli-responsive carrier systems 
As discussed in brief above, in order to be optimally effective, the drug delivery systems 
must release their payloads at the desired site of action, i.e. the pannus tissue. In the realm 
of cancer drug delivery, numerous pH- and temperature-responsive  carrier systems, in the 
form of conjugates, dendrimers, liposomes, and micelles,  have been developed (Ganta et al., 
2008). Although the same potential also exists for rheumatoid arthritis drug delivery, 
particularly in light of the lower pH of the pannus tissue relative to native tissue, to the 
authors’ knowledge, only two pH-responsive systems, dexamethasone-HPMA conjugates 
(P-Dex) and dexamethasone-PEG conjugates (PEG-DEX), have been reported. Drug release 
was shown to increase as the pH decreased. In vitro and in vivo tests were used to 
demonstrate that P-Dex and PEG-DEX are more effective than free dexamethasone in 
regards to reducing the production of proinflammatory mediators, preventing joint damage, 
and targeting inflamed tissue (Liu et al., 2010; Quan et al., 2010). In addition to temperature 
and pH, other environmental triggers may be used. For example, elevated elastace levels 
have been closely linked with inflammation and the increased enzymatic activity maybe be 
used for cleavage. The upregulation in enzymes may additionally serve as a means of active 
targeting (Meers, 2001).    
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5.4 Gene therapy 
Given the nature of rheumatoid arthritis, gene therapy, whereby nucleic acids are 
introduced to a cell to either “turn off” select genes or upregulate therapeutic genes, is an 
attractive alternative treatment strategy (Jorgensen & Apparailly, 2010). This approach is 
limited, however, by the necessity for local administration and low transfection efficiency; 
therefore, for practical use, drug delivery systems for gene therapy will be required. Small 
interfering RNA (siRNA), in particular, may be used to knockdown the expression of 
proinflammatory proteins at the mRNA level. Cationic liposomes, referred to as lipoplexes, 
have been designed to facilitate systemic delivery of siRNA for rheumatoid arthritis 
treatment (Khoury et al., 2006, 2008). When administered intravenously to arthritic mice, 
anti-TNF-, anti-IL-1, anti IL-6, and anti IL-18 siRNA successfully reduced inflammation, 
bone and cartilage degradation, and secretion of a number of proinflammatory cytokines, 
including TNF-and IL-1 (Khoury et al., 2006, 2008). Similarly, intraperitoneal 
administration of anti-TNF- siRNA complexed with chitosan nanoparticles to arthritic 
mice resulted in a significant reduction in joint swelling, cartilage degradation, and 
inflammatory cell infiltration (Fernandes et al., 2008). Chitosan nanoparticles were also used 
to deliver the IL-1 receptor antagonist (IL-1Ra) gene to arthritic rats (Fernandes et al., 2008). 
Rats treated with the chitosan-gene delivery system showed reduced bone turnover, as well 
as decreased expression of IL-1and PGE2, relative to control rats. The efficacy of the 
chitosan-IL-1Ra nanoparticles was further improved by modification with folate for active 
targeting (Fernandes et al., 2008). An innovative strategy towards gene therapy was 
designed by encapsulating a nuclear factor kappa B (NF-B) decoy into stealth lipid-based 
nanoparticles that were surface modified with folate (Hattori et al., 2006). NF-B regulates 
proinflammatory gene expression and is, therefore, a critical component of rheumatoid 
arthritis pathogenesis (Brown et al., 2008; Simmonds & Foxwell, 2008).  In vitro, the 
nanoparticles were shown to release the NF-B into the cytoplasm, as indicated by a 
reduction in NF-B translocation into the nucleus (Hattori et al., 2006), which presumably 
will result in a decreased expression of proinflammatory cytokines and growth factors.  
6. Conclusion 
Although the advent of biologics markedly increased the number of available treatment 
options, numerous rheumatoid arthritis patients still use, either alone or in combination, 
NSAIDs, GCs, and conventional DMARDs. All of these compounds are associated with 
severe negative side effects resultant from non-specific organ toxicity. In some cases, the 
side effects necessitate the cessation of a treatment option that may be effectively altering the 
course of the disease. The application of drug delivery strategies, as outlined herein, 
promises to improve patient outcome by reducing the likelihood of an adverse reaction to 
NSAIDs, GCs, and biologic and conventional DMARDs. These same strategies may be 
extended in the future to facilitate diagnostic imaging and gene therapy, thereby further 
increasing the possibility of successfully controlling the progression of the disease in all 
people that suffer from rheumatoid arthritis.  
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